A Phase 3 interventional study of Alirocumab and Rosuvastatin in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 93 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-07.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 15th largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 19th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 305 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2012, is one of 4 in phase 3, and was the 6th registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab (REGN727/SAR236553) as an add-on therapy to other LMT in patients with hypercholesterolemia at high cardiovascular (CV) risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with LDL-C greater than or equal to 70 mg/dL at the screening visit and who are not adequately controlled with a stable daily dose of rosuvastatin, with or without other LMT.
OR
Exclusion Criteria:
(The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
Drug: Rosuvastatin · Drug: Placebo
Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
Drug: Rosuvastatin · Drug: Ezetimibe · Drug: Placebo
Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
Drug: Alirocumab · Drug: Rosuvastatin · Drug: Placebo
Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.
Drug: Rosuvastatin · Drug: Placebo
Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.
Drug: Rosuvastatin · Drug: Ezetimibe · Drug: Placebo
Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
Drug: Alirocumab · Drug: Rosuvastatin · Drug: Placebo
Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Also known as: REGN727/SAR236553
Rosuvastatin over-encapsulated tablets orally.
Also known as: Crestor
Ezetimibe over-encapsulated tablets orally.
Also known as: Ezetrol
Placebo for alirocumab and ezetimibe.
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
Time frame: Up to Week 24
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).
Time frame: Up to Week 24
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
Time frame: Up to Week 24
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).
Time frame: Up to Week 24
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
The study was conducted at 79 sites in 8 countries. Overall, 672 participants were screened between 24 October 2012 and 27 September 2013, 367 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.
| Milestone | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Started | 48 | 48 | 49 | 53 | 53 | 54 |
| Treated | 48 | 48 | 49 | 53 | 53 | 54 |
| Completed | 43 | 34 | 38 | 45 | 44 | 41 |
| Not completed | 5 | 14 | 11 | 8 | 9 | 13 |
| Withdrew: Participant moved | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 6 | 3 | 3 | 2 | 2 |
| Withdrew: Poor compliance to protocol | 1 | 2 | 2 | 0 | 0 | 2 |
| Withdrew: Other than specified | 2 | 6 | 5 | 4 | 7 | 9 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis | -16.3 ± 4.1 | -14.4 ± 4.4 | -50.6 ± 4.2 | -15.9 ± 7.1 | -11.0 ± 7.2 | -36.3 ± 7.1 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | -18.3 ± 3.3 | -20.3 ± 3.6 | -53.5 ± 3.5 | -17.0 ± 6.9 | -16.5 ± 6.9 | -41.5 ± 6.9 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | -17.1 ± 4.1 | -17.4 ± 4.2 | -49.6 ± 4.1 | -22.1 ± 5.3 | -19.3 ± 5.4 | -32.3 ± 5.2 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis | -17.2 ± 3.6 | -20.3 ± 3.8 | -52.6 ± 3.6 | -22.9 ± 5.2 | -21.8 ± 5.2 | -35.1 ± 5.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | -7.3 ± 3.0 | -9.7 ± 3.1 | -36.5 ± 3.1 | -9.8 ± 4.1 | -11.2 ± 4.3 | -28.3 ± 4.3 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first).
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis | -8.8 ± 2.6 | -11.2 ± 2.7 | -39.5 ± 2.6 | -12.7 ± 4.0 | -12.6 ± 4.1 | -30.4 ± 4.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis | -11.3 ± 3.4 | -13.4 ± 3.7 | -42.7 ± 3.5 | -11.2 ± 5.1 | -12.9 ± 5.2 | -31.4 ± 5.2 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first).
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis | -12.9 ± 2.8 | -17.5 ± 3.1 | -45.7 ± 2.9 | -14.9 ± 4.2 | -18.2 ± 4.2 | -35.6 ± 4.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis | -8.3 ± 2.4 | -8.7 ± 2.6 | -28.9 ± 2.5 | -8.5 ± 3.6 | -12.4 ± 3.6 | -20.6 ± 3.6 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | -8.1 ± 3.2 | -12.1 ± 3.3 | -36.1 ± 3.2 | -13.7 ± 3.3 | -14.3 ± 3.3 | -29.0 ± 3.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | -11.7 ± 3.5 | -16.3 ± 3.6 | -41.2 ± 3.5 | -18.0 ± 3.6 | -18.7 ± 3.7 | -29.8 ± 3.6 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | -8.9 ± 2.6 | -11.8 ± 2.7 | -29.0 ± 2.6 | -13.8 ± 2.8 | -13.9 ± 2.8 | -19.4 ± 2.7 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
| percentage of participants | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis | 45.0 | 57.2 | 84.9 | 40.1 | 52.2 | 66.7 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).
| percentage of participants | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis | 47.0 | 60.5 | 86.4 | 41.3 | 54.8 | 70.4 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
| percentage of participants | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 31.3 | 43.1 | 77.8 | 29.9 | 43.6 | 60.1 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).
| percentage of participants | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis | 34.8 | 46.7 | 76.5 | 30.6 | 45.1 | 66.1 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis | -4.0 ± 4.3 | -4.3 ± 4.5 | -27.9 ± 4.1 | -5.2 ± 4.8 | -5.8 ± 4.6 | -22.7 ± 5.1 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | 1.7 ± 2.4 | 4.0 ± 2.5 | 9.1 ± 2.4 | 1.5 ± 2.3 | -1.8 ± 2.3 | 7.2 ± 2.3 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | -1.8 ± 4.5 | -8.3 ± 4.8 | -11.2 ± 4.6 | -9.9 ± 4.1 | -11.1 ± 4.3 | -8.7 ± 4.5 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis | 5.4 ± 1.9 | 5.0 ± 1.9 | 6.7 ± 1.9 | 2.9 ± 1.9 | -0.9 ± 1.9 | 6.7 ± 2.0 |
Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis | -0.7 ± 3.5 | -3.9 ± 3.6 | -20.7 ± 3.5 | 3.5 ± 4.2 | 7.9 ± 4.1 | -16.0 ± 4.2 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | 0.7 ± 2.1 | 0.2 ± 2.2 | 5.9 ± 2.1 | 0.6 ± 2.5 | 3.1 ± 2.5 | 8.0 ± 2.5 |
Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | 8.1 ± 4.1 | -8.2 ± 4.2 | -14 ± 4.1 | -2.7 ± 4.0 | -12.4 ± 4.0 | -10.1 ± 4.0 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis | 4.0 ± 1.6 | 2.6 ± 1.6 | 4.3 ± 1.6 | 0.9 ± 1.8 | 1.8 ± 1.8 | 9.1 ± 1.8 |
Collected over From Baseline to Week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 20 mg | — | 4/48 (8.3%) | 11/48 (22.9%) |
| Ezetimibe 10 mg + Rosuvastatin 10 mg | — | 5/48 (10.4%) | 11/48 (22.9%) |
| Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | — | 2/49 (4.1%) | 11/49 (22.4%) |
| Rosuvastatin 40 mg | — | 4/53 (7.5%) | 20/53 (37.7%) |
| Ezetimibe 10 mg + Rosuvastatin 20 mg | — | 3/53 (5.7%) | 12/53 (22.6%) |
| Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg | — | 4/54 (7.4%) | 15/54 (27.8%) |
| Event | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 1/48 | 0/48 | 0/49 | 0/53 | 0/53 | 0/54 |
| Spinal cord infectionInfections and infestations | 0/48 | 1/48 | 0/49 | 0/53 | 0/53 | 0/54 |
| ObesityMetabolism and nutrition disorders | 1/48 | 0/48 | 0/49 | 0/53 | 0/53 | 0/54 |
| Non-Small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/48 | 1/48 | 0/49 | 0/53 | 0/53 | 0/54 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/48 | 0/48 | 0/49 | 0/53 | 0/53 | 0/54 |
| Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/48 | 0/48 | 0/49 | 0/53 | 0/53 | 0/54 |
| ParaesthesiaNervous system disorders | 0/48 | 1/48 | 0/49 | 0/53 | 0/53 | 0/54 |
| SyncopeNervous system disorders | 0/48 | 1/48 | 0/49 | 0/53 | 0/53 | 1/54 |
| HaematuriaRenal and urinary disorders | 0/48 | 1/48 | 0/49 | 0/53 | 0/53 | 0/54 |
| UrosepsisInfections and infestations | 0/48 | 0/48 | 1/49 | 0/53 | 0/53 | 0/54 |
| Event | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/48 | 2/48 | 2/49 | 6/53 | 3/53 | 2/54 |
| Upper respiratory tract infectionInfections and infestations | 3/48 | 0/48 | 2/49 | 6/53 | 4/53 | 4/54 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/48 | 1/48 | 2/49 | 5/53 | 2/53 | 0/54 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/48 | 0/48 | 4/49 | 2/53 | 1/53 | 0/54 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/48 | 3/48 | 0/49 | 1/53 | 1/53 | 4/54 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/48 | 3/48 | 1/49 | 0/53 | 0/53 | 0/54 |
| DizzinessNervous system disorders | 3/48 | 1/48 | 1/49 | 2/53 | 1/53 | 2/54 |
| NauseaGastrointestinal disorders | 1/48 | 1/48 | 3/49 | 1/53 | 1/53 | 0/54 |
| HeadacheNervous system disorders | 0/48 | 1/48 | 0/49 | 3/53 | 0/53 | 0/54 |
| DiarrhoeaGastrointestinal disorders | 0/48 | 2/48 | 0/49 | 3/53 | 0/53 | 2/54 |
| Age, Continuous(years) | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75/up to 150 + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 61.5 ± 11.15 | 60.4 ± 10.38 | 62.2 ± 11.11 | 60.6 ± 10.11 | 63.1 ± 10.2 | 57.9 ± 8.86 | 60.9 ± 10.4 |
| Sex: Female, Male(Participants) | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75/up to 150 + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 15 | 22 | 18 | 15 | 22 | 26 | 118 |
| Male | 33 | 26 | 31 | 38 | 31 | 28 | 187 |
| Low density lipoprotein cholesterol (LDL-C) in mg/dL(mg/dL) | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75/up to 150 + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 105.9 ± 36.0 | 102.4 ± 41.9 | 107.3 ± 26.4 | 112.9 ± 43.3 | 119.0 ± 48.0 | 118.3 ± 32.2 | 111.3 ± 39.0 |
| LDL-C in mmol/L(mmol/L) | Rosuvastatin 20 mg | Ezetimibe 10 mg + Rosuvastatin 10 mg | Alirocumab 75/up to 150 + Rosuvastatin 10 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Rosuvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 2.743 ± 0.933 | 2.653 ± 1.085 | 2.78 ± 0.684 | 2.924 ± 1.122 | 3.082 ± 1.243 | 3.065 ± 0.834 | 2.882 ± 1.009 |
Ran from Nov 2012 to primary completion in Apr 2014, 17 months.
Results were first posted in Oct 2015, 1 year 5 months after primary completion. A results delay was requested in Jan 2015.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is close to that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab